Chronic hepatitis B in children and adolescents Massimiliano Paganelli, Xavier Stephenne, Etienne M. Sokal  Journal of Hepatology  Volume 57, Issue 4, Pages 885-896 (October 2012) DOI: 10.1016/j.jhep.2012.03.036 Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Who and when to treat: algorithm for treatment of children and adolescents with chronic hepatitis B. Journal of Hepatology 2012 57, 885-896DOI: (10.1016/j.jhep.2012.03.036) Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Comparison between available treatments in term of HBeAg seroconversion (light blue bars), undetectable HBV DNA (blue bars) and resistant mutations emergence (dark blue bars). Pediatric clinical trials (P) are compared to studies on adult patients (A). (See below-mentioned references for further information.) Journal of Hepatology 2012 57, 885-896DOI: (10.1016/j.jhep.2012.03.036) Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Fig. 3 HBeAg seroconversion rates in children treated with INF-alfa (light blue bars) as compared to untreated subjects (dark blue bars). Differences between the two groups in each study are not statistically significant. Journal of Hepatology 2012 57, 885-896DOI: (10.1016/j.jhep.2012.03.036) Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2012 57, 885-896DOI: (10. 1016/j. jhep. 2012. 03 Copyright © 2012 European Association for the Study of the Liver Terms and Conditions